licensing opportunities

View All

Delveinsight
LAG-3 Antagonists, TIM-3 Antagonists; OX40 Agonists- Pipeline Insights, 2016 – A DelveInsight Report

DelveInsight, the leading market research and consulting company has added new report “LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists- Pipeline Insights, 2016” to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise pro...

Find More

Delveinsight
Chimeric Antigen Receptor T cell Immunotherapy Market Analysis and Forecast

DelveInsight, the leading market research and consulting company has added new report    “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016”to its portfolio. Reports Highlights: ·      CAR-T cell Therapy Pipeline scenario ·      Collaborations &...

Find More

Delveinsight
Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report  Head and Neck Squamous Cell Carcinoma -Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clien...

Find More

Delveinsight
Peripheral Lung Cancer Pipeline Insights, 2016

DelveInsight, the leading market research and consulting company has added new report Peripheral Lung Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date inf...

Find More

Delveinsight
DelveInsight’s Market Research Reports

DelveInsight has established its strong presence in therapeutic areas and has launched Analytical Reports on indication, mechanism of actions, drugs, Global API Manufacturers and specialized Reports on Gene Therapy, Anticoagulants, PD-1 and PDL-1, CART and Antibody Drug conjugates. After tremendous success last yea...

Find More

Delveinsight
Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015

DelveInsight, the leading market research and consulting company has added new report  Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients w...

Find More

Delveinsight
Antibody-Drug Conjugate Market Outlook, 2015 Report in Market Now!

Launch of DelveInsight’s Antibody-Drug Conjugate Report DelveInsight’s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-dr...

Find More

Delveinsight
A CRISPR-Cas9 approach for Gene Therapy: The Hot New R&D Field!

Only a hundred and fifty years have passed since Gregor Mendel’s discovery of simple Mendelian inheritance. In a remarkably short amount of time humans have achieved such impressive feats as sequencing the entire human genome and gaining understanding of the causes of most genetic disease. Now that researchers have ...

Find More

Delveinsight
Are you ready to embrace Gene Therapy?

Gene Therapy: The “Big Value” Market! Gene therapy has been under scientific research for over 2 decades, but viable therapies have yet to gain commercial acceptance due to safety and delivery-related issues. However, Pfizer’s move and some other recent developments in the industry suggest that the therapy may be ...

Find More

Delveinsight
DelveInsight’s Ophthalmologic disorders based Gene Therapy Reports

Gene Therapy: Eye for the cure! Recent technical advances have led to the demonstration of the molecular basis of various ocular diseases. Gene transfer into ocular tissues has been demonstrated with growing functional success and may develop into a new therapeutic tool for clinical ophthalmology.  There are pr...

Find More